ClinicalTrials.gg
Active, not recruitingNCT06608641Updated Mar 17, 2025

Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

A Phase 3 interventional study of Endoxifen enteric-coated tablet (8 mg) and Placebo Tablets in Bipolar 1 Disorder, sponsored by Jina Pharmaceuticals Inc.. Active, not recruiting at 12 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Jina Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as active, not recruiting.
  • Registered 5 months after the study started (first participant enrolled Mar 2024, registered Sep 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
490
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adult population. Endoxifen is an active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the Bipolar I disorder patient population compared to a placebo arm. Endoxifen will be compared to a placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is safe and active.

Read the detailed description

Protein Kinase C (PKC) plays a major role in the regulation of both pre and postsynaptic neurotransmission. Excessive activation of PKC results in symptoms related to bipolar disorder. PKC exists as a family of closely related subspecies, has a heterogeneous distribution in the brain (with particularly high levels in presynaptic nerve terminals), and plays a crucial role in the regulation of neuronal excitability, neurotransmitter release, regulation of synaptic plasticity and various forms of learning and memory. Research findings show that the PKC pathway can be used as a target for developing treatment strategies for bipolar disorder. Endoxifen exhibited activity in inhibiting the PKC activity.

In patients with acute bipolar mania, rapid reduction of symptoms is a key treatment goal; however, there is also a need for effective maintenance of effect treatment beyond the period of acute stabilization. The current study will evaluate the efficacy and safety of Endoxifen in Bipolar I Disorder patients against a control placebo arm.

02

Conditions studied

  • Bipolar 1 Disorder
03

In context

Lead sponsor

Jina Pharmaceuticals Inc. is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male ≥18 to ≤65 years of age and female patients (12 months with no menses without an alternative medical cause) willing to give written along with at least one first degree relative (the legally acceptable representative [LAR]) to participate in the study before initiating any study related procedures.
  2. Six months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL; OR have had surgical bilateral oophorectomy (with or without hysterectomy) at least six months ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment if she is considered not of .
  3. Patients must have a diagnosis of bipolar I disorder and currently display an acute manic episode with or without mixed features according to criteria as judged by the Investigator.
  4. Young Mania Rating Scale (YMRS) total score of > 25 and ≥4 on two of four core items (irritability, speech, content, disruptive/aggressive behavior) at screening and at randomization (baseline). The optimal YMRS23 severity threshold of 25 was chosen as this corresponds to a Positive Predictive Value (PPV) of 83%, signifying that 83% of patients with a baseline score ≥ 25 are at least "Markedly ill".
  5. Score of >4 in Severity of illness criteria of Clinical Global Impressions- bipolar disorder (CGI-BP) Scale for overall illness at screening and at randomization (baseline).
  6. Ready for voluntary hospitalization (along with the accompanying LAR if required and as advised by the Investigator) for the current manic episode for a minimum of 2 days prior to randomization through 21 days of in-patient treatment period.
  7. Last intake of the medication(s) for BPD should be 2-7 days prior to randomization depending upon the individual drug's plasma half-life.
  8. Patient and / or LAR understand and agree to comply with all the study requirements.
  9. Male patients of child begetting potential must be practicing adequate , and any female partners must agree to the use of, highly effective contraception. Documentation should be provided for surgical sterilization for male patients not of child begetting potential.
  1. Patient has not taken and agrees not to take any medication or therapy prohibited by the protocol (refer to listing in Section 14.7) for the entire study period.
  1. Patients not having any significant diseases or abnormal findings except BPD during screening-including medical history, physical examination, laboratory evaluations, 12-lead and X-ray chest (postero- anterior view) recording, etc. which is likely to adversely affect patient\'s safety and may impact the clinical outcome of the study by participating in the study or study objectives in Investigator\'s opinion.
  1. Subjects judged clinically not to be at serious suicide risk, (all responses to the Baseline C-SSRS as "No"), or homicidal risk per clinical questioning.

Exclusion criteria

Exclusion Criteria:

  1. Newly diagnosed patients not having any suitable treatment exposure in the past for their bipolar mood disorder.
  2. ≥ 20% improvement in YMRS total scores between screening and randomization visits.
  3. Patients who meet DSM-5criteria for any psychiatric disorder other than Bipolar I Disorder with Acute manic episodes with or without mixed features
  4. Patients with seizure disorder
  5. Obsessive compulsive disorder or any other co-morbid Axis I anxiety disorder
  6. Patients with borderline or anti-social personality disorder of sufficient current severity to interfere with conduct of the study
  7. Patients with classical premenopausal symptoms were found at risk of developing intolerable hot flushes, irregular vaginal bleeding.
  8. Use of the following medications:

    • Antihypertensive agents if stable dose has not been administered for at least 1 month before randomization
    • Antidepressants in the week (or a period of 5 half-lives of the drug) prior to randomization
    • Continuous daily or standing orders use of benzodiazepines during the month preceding screening (approximately 5 weeks prior to screening)
    • Potent cytochrome P450 (CYP) inducers and CYP2D6/ inhibitors 14 days prior to randomization
    • Depot antipsychotic medications within 1 dosing interval prior to randomization
    • Use of systemic estrogens 6 weeks prior to randomization
    • Patients currently on carbapenem agents
  9. Any of the following laboratory abnormalities

    • Serum ≥ 1.5 times
    • Serum /ALT ≥ 2.5 times ULN
    • Serum TSH >10% above the ULN, regardless of treatment for hypothyroidism or hyperthyroidism
    • Serum triglyceride level > 2.5 times ULN
  10. Patients with the following cardiac conditions are excluded:

    • Recent myocardial infarction (\<12 months)
    • prolongation (screening with QTc > 450 msec for men, QTc > 470 msec for women)
    • History of QTc prolongation or using concomitant medications (as judged by the Investigator) which prolong QTc interval
    • Sustained cardiac arrhythmia or history of sustained cardiac arrhythmia
    • Decompensatory congestive heart failure
    • Complete left bundle branch block
    • First-degree heart block with PR interval > 0.22 seconds
  11. Presence of a coagulation disorder; active or past history of venous thromboembolism including deep venous thrombosis or pulmonary embolism
  12. Current prolonged immobilization
  13. History or current presence of retinal pathology including retinal vein thrombosis
  14. Increased risk of stroke as per the Investigator's discretion
  15. History of or intolerance to tamoxifen, or any other ingredients of the preparation
  16. Serious, unstable illnesses including hepatic, renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease as per history and medical examination.
  17. Drug screen positive for any drug of abuse at screening, (except for benzodiazepines used in therapeutic dose for management of acute mania), active substance abuse in the past 2 months or history of substance dependence (excluding nicotine and caffeine) within 3 months of screening.
  18. History of breast or uterine cancer, or abnormal uterine bleeding.
  19. Current leukopenia or thrombocytopenia as judged by the Investigator in the best health interest of the subject.
  20. suicidal (subject responds "Yes" to any category for Baseline C-SSRS) or homicidal ideation per clinical questioning.
  21. Participation in a clinical trial of another drug within 30 days prior to screening.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
490 participants (estimated)

Study arms

  • Experimental
    Endoxifen Arm

    Endoxifen enteric-coated tablet (8 mg). Patients will continue treatment with their initial randomized medication for 3 weeks

    Drug: Endoxifen enteric-coated tablet (8 mg)

  • Placebo comparator
    Placebo Arm

    Placebo tablets. Patients will continue administration with their initial randomized medication for 3 weeks

    Drug: Placebo Tablets

Interventions

  • DrugEndoxifen enteric-coated tablet (8 mg)

    Patients will continue treatment with their initial randomized medication for 3 weeks

  • DrugPlacebo Tablets

    Patients will be treated with Endoxifen Placebo Tablets for 21 days

06

What researchers measure

Primary outcomes

  1. Efficacy - mean change from baseline to Day 21 in the total YMRS score

    Primary efficacy endpoint will be the mean change from baseline to Day 21 in the total YMRS score. The point estimate and 95% confidence interval for the mean change from Day 0 (baseline) to Day 21 in total YMRS score for the difference between test and placebo control treatment will be computed and reported for mITT set. Superiority of test over placebo will be claimed if 95% confidence interval for mean change from Day 0 (baseline) to Day 21 in total YMRS score for the difference between test and placebo control treatment will exclude zero for mITT set.

    Time frame: 27 days

Secondary outcomes

  1. Secondary efficacy endpoints

    * Percentage of patients with improvement of ≥ 50% in total YMRS from baseline. * Clinical Global Impression-Bipolar (CGI-BP) score at the end of study. * Mean change from baseline to the end of treatment in Montgomery-Åsberge Depression Rating Scale (MADRS) total score. * Improvement in Clinical Global Impression-Severity of Illness scale (CGI-S) score. * Columbia-Suicide Severity Rating Scale (C-SSRS) score at the end of treatment. * Percentage of patients needing lorazepam/diazepam for controlling acute agitation/akathisia. * Percentage of patients requiring rescue medications and withdrawal from the study. * To evaluate trough concentrations of Endoxifen.

    Time frame: 21 days

07

Study locations

12 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Jun 2025, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2024
First posted
Sep 23, 2024
StartActual
Mar 19, 2024
Primary completionEst.
Jun 2025
CompletionEst.
Dec 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06608641
Lead sponsor
Jina Pharmaceuticals Inc.
Collaborators
Novum Pharmaceutical Research Services
Responsible party
Sponsor
First posted
Sep 23, 2024
Start date
Mar 19, 2024
Primary completion
Jun 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Mar 17, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion